Welcome to our dedicated page for Scynexis news (Ticker: SCYX), a resource for investors and traders seeking the latest updates and insights on Scynexis stock.
SCYNEXIS Inc. (SCYX) is a clinical-stage biotechnology company advancing innovative therapies for severe fungal infections. This page aggregates official news and press releases related to their antifungal pipeline, including ibrexafungerp and SCY-247 development milestones.
Investors and healthcare professionals will find timely updates on clinical trial data, regulatory submissions, and strategic partnerships. Content includes earnings reports, research publications, and manufacturing announcements, all sourced directly from the company.
Key areas covered: Phase III trial results, FDA communications, intellectual property updates, and collaborative research initiatives. Bookmark this page for streamlined access to SCYNEXIS's latest developments in antifungal therapeutics.
SCYNEXIS, a biotechnology company, has announced its presentation of interim data on various infection types from the ongoing Phase 3 FURI and CARES studies, along with the innovative MARIO trial design. This will occur at the 33rd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) from April 15-18, 2023, in Copenhagen, Denmark. Key presentations include:
- Oral Ibrexafungerp outcomes in urinary tract infections.
- Evaluation of Ibrexafungerp's efficacy alone and with other antifungals.
- A novel protocol for Ibrexafungerp as step-down therapy.
Ibrexafungerp, a groundbreaking antifungal agent, shows promise against drug-resistant infections. It has received FDA designations for invasive candidiasis and aspergillosis, highlighting its potential in treating difficult infections.
SCYNEXIS has secured an exclusive agreement with GSK for the commercialization and development of BREXAFEMME (ibrexafungerp), including an upfront payment of $90 million and potential future milestone payments totaling $503 million. The company retains rights to all other fungerp assets. As of Q4 2022, SCYNEXIS reported $1.4 million in net sales for BREXAFEMME with 5,125 prescriptions written. The company has completed enrollment in several Phase 2 and Phase 3 trials for ibrexafungerp and has a projected cash runway of over two years post-GSK transaction. However, net loss for 2022 was $62.8 million.
FAQ
What is the current stock price of Scynexis (SCYX)?
What is the market cap of Scynexis (SCYX)?
